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Abstract
Background: The impact of male sex as a determinant of health outcomes in systemic sclerosis-associated
pulmonary arterial hypertension (SSc-PAH) is controversial. The primary objective of this study was to evaluate the
effect of sex on survival in patients with SSc-PAH. The secondary objectives were to evaluate the effect of sex on
age of PAH diagnosis, time from SSc diagnosis to PAH diagnosis, and SSc disease manifestations.
Methods: Sex-based disparities were evaluated in a cohort of SSc-PAH patients with a primary outcome of time from
PAH diagnosis to all-cause mortality. Secondary outcomes were differences in age of diagnosis, disease duration, and
SSc manifestations. Survival differences were evaluated using Kaplan-Meier and Cox proportional hazard models.
Results: We identified 378 SSc-PAH (58 males, 320 females) patients, with a female:male ratio of 5.5:1. Males had a
shorter mean ± standard deviation time from SSc diagnosis to PAH diagnosis (1.7 ± 14 versus 5.5 ± 14.2 years); shorter
PAH duration (3.5 ± 3.1 versus 4.7 ± 4.2 years), increased frequency of renal crisis (19 % versus 8 %, relative risk (RR) 2.33,
95 %CI 1.22, 4.46), interstitial lung disease (67 % versus 48 %, RR 1.41, 95 %CI 1.14, 1.74), and diffuse subtype (40 %
versus 22 %, RR 1.84, 95 %CI 1.26, 2.69). Males appeared to have decreased 1-, 2-, 3-, and 5-year survival (83.2 %, 68.7 %,
53.2 %, 45.6 %) compared to females (85.7 %, 75.7 %, 66.4 %, 57.4 %). However, there was no difference in mortality
between sexes (HR 1.43 (95 %CI 0.97, 2.13).
Conclusions: Sex disparities appear to exist in the frequency of PAH, time to PAH diagnosis, PAH disease duration and
SSc disease burden. However, male sex does not independently impact SSc-PAH survival.
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Background
Systemic sclerosis (SSc) is a systemic autoimmune rheum-
atic disease characterized by vasculopathy and fibrosis that
primarily affects females with a female:male ratio 3–4:1
[1]. Sex hormones likely play an important role in the ob-
served female preponderance in SSc [2]. Although female
prevalence is high, several authors have reported that male
sex is associated with decreased survival [3–7]. Male sex
has been associated with an increased risk of mortality in
SSc patients above that observed for males in the general
population [7].
SSc-associated pulmonary arterial hypertension (SSc-
PAH) is a leading cause of SSc-related mortality, with a
prevalence of approximately 7 % [8]. Little is known
about the effect of sex on disease onset, time to PAH
diagnosis, and survival in patients with SSc-PAH [9, 10].
In a cohort study of 259 SSc-PAH patients, male sex was
associated with increased risk of mortality (hazard ratio
(HR) 2.2, 95 % confidence interval (CI) 1.35, 3.55) [11].
However, in another cohort study of 152 SSc-PAH patients,
male sex was not an independent risk factor for mortality
(HR 2.02, 95 %CI 0.65, 6.2) [12]. Furthermore, sex was not
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an independent risk factor in a cohort of patients with
connective tissue disease-associated PAH (22 % of whom
had SSc-PAH) and idiopathic PAH (IPAH) (HR 0.78,
95 %CI 0.40, 1.51) [13]. Using data from the REVEAL
registry, Benza et al. found that men >60 years of age
had poorer 1-year survival compared to females (HR
2.2, 95 %CI 1.6, 3.0) [14]. This finding was confirmed
by Shapiro et al., who reported sex differences in 2-year
survival from enrolment in the REVEAL registry among
men diagnosed with group I PAH aged >60 years (HR
1.67, 95 %CI 1.28, 2.17) [15]. They also noted that male
sex was associated with poorer survival for the IPAH sub-
group of group I PAH patients across all age groups [15].
Humbert et al. reported that among patients with IPAH,
familial, and anorexigen-associated PAH, females had bet-
ter survival (HR 0.52, 95 %CI 0.30, 0.88 [16]. However,
Fisher et al. reported that there was no significant differ-
ence between males and females in 3-year survival for pa-
tients diagnosed with IPAH and SSc-PAH combined [17].
Thus, the current literature on the effect of sex on
SSc-PAH is limited and conflicted. The effect of sex on
age of onset, time to diagnosis, disease duration, disease
manifestations and survival in SSc-PAH is not well
understood. The aim of this study is to improve our un-
derstanding of the sex-based disparities in SSc-PAH.
The primary objective of this study was to evaluate the
effect of sex on survival in patients with SSc-PAH. The
secondary objectives were to evaluate the effect of sex
on age of PAH diagnosis, time from SSc diagnosis to
PAH diagnosis, and SSc disease manifestations.
Methods
Patients
The University Health Network Pulmonary Hyperten-
sion Programme has the largest published single-center
longitudinal cohort in Canada [18]. Patients are pro-
spectively followed every 6 to 12 months using a stan-
dardized protocol. Adult SSc-PAH patients seen between
1998 and January 1, 2014 were included if they fulfilled
the American College of Rheumatology (ACR) – European
League Against Rheumatism (EULAR) classification cri-
teria for SSc [19], and had PAH confirmed by catheteri-
zation with a mean pulmonary artery pressure (mPAP)
>25 mm Hg, pulmonary capillary wedge pressure (PCWP)
<15 mm Hg and pulmonary vascular resistance (PVR) >3
Wood units on catheterization [20]. Patients with another
etiology for PAH (e.g. human immunodeficiency virus,
anorexigen use, portal hypertension, congenital cardiac ab-
normalities) were excluded.
Exposure
Sex was defined as self-reported biological and physio-
logical characteristics at birth, and characterized as male
or female. Gender (roles, behaviours, activities, and
attributes that a given society considers appropriate) was
not assessed. Patients were excluded from analysis if
they had a known history of sex chromosome abnormal-
ities or had undergone sex reassignment surgery.
Outcome
The primary outcome of the study was the time from
PAH diagnosis to death from all causes. Patients who
were alive as of June 1, 2014 were censored. PAH diagno-
sis was defined as the date of right heart catheterization.
SSc diagnosis was defined as the date a diagnosis of SSc
was made by a physician. Dates of death were obtained
from the clinic chart, hospital electronic record or obitu-
ary. Secondary outcomes included sex differences in age at
PAH diagnosis, time from SSc diagnosis to PAH diagnosis,
PAH disease duration, subtype of SSc (limited, diffuse),
and SSc manifestations (Raynaud’s phenomenon, digital
ulceration, esophageal dysmotility, telangiectasia, intersti-
tial lung disease (bibasilar reticular abnormalities with
minimal ground-glass on high-resolution computerized
tomography (CT) of the thorax) and serology (centromere,
topoisomerase I (ScL-70); RNA polymerase III was not
available). Comorbidities (coronary artery disease, hyper-
tension, diabetes, hyperlipidemia, atrial fibrillation, and
stroke), medications (warfarin, calcium channel blocker,
endothelin receptor antagonist, prostaglandin analogue,
and phosphodiesterase inhibitors), pulmonary function
and hemodynamic measurements were compared.
Analysis
All statistical analysis was done using RStudio (version
0.98.932, R Foundation for Statistical Computing, 2012).
The Shapiro-Wilk statistic was used to test for normality.
Continuous data were not normally distributed. Baseline
characteristics for males and females were analyzed using
standardized differences, and a difference of 25 % was
considered significant. Use of standardized differences is a
method of comparing two groups, independent of sample
size. For dichotomous variables we also reported the
relative risk (RR). Survival data were plotted using Kaplan-
Meier curves and significance was tested using the log-
rank test. Independent predictors of survival were evaluated
using Cox regression analysis. Hazard ratios (HR) are re-
ported with 95 % confidence intervals (95 % CI). Univer-
sity Health Network (12-5253-AE) and Mount Sinai
Hospital (12-0233-C) research ethics board approvals
were obtained for the conduct of this study. The ethics
boards waived the need for consent, as this was a retro-
spective study with a high mortality rate.
Results
SSc-PAH patient characteristics
A total of 1142 charts were reviewed and 378 SSc-PAH
patients were identified of whom 58 (15.3 %) were male
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and 320 (84.7 %) were female. All patients fulfilled the
ACR-EULAR classification criteria for SSc. The female:-
male ratio was 5.5:1. The mean age at diagnosis was
54.5 ± 11.0 years for males and 57.3 ± 13.0 years for fe-
males. Males had a shorter mean time from SSc diagno-
sis to PAH diagnosis (1.7 ± 14 versus 5.5 ± 14.2 years;
standardized difference 93 %) and shorter PAH disease
duration (3.5 ± 3.1 versus 4.7 ± 4.2 years, standardized
difference 29 %). Males had an increased frequency of
renal crisis (19 % versus 8 %, relative risk (RR) 2.33,
95 %CI 1.22, 4.46), interstitial lung disease (67 % versus
48 %, RR 1.41, 95 %CI 1.14, 1.74) and diffuse cutaneous
disease (40 % versus 22 %, RR 1.84, 95 %CI 1.26, 2.69).
Adjusting for the presence of interstitial lung disease had
marginal to no effect on the effect of male sex on pulmon-
ary hypertension age of diagnosis, time from SSc diagnosis
to PAH diagnosis and pulmonary hypertension disease
duration. There were no significant differences between
males and females in the presence of Raynaud’s phe-
nomenon, telangiectasia, digital ulcers, esophageal dysmo-
tility, serology, 6-minute walk distance, World Health
Organization (WHO) functional class, brain natriuretic
peptide levels, comorbidities and medications (Table 1).
SSc-PAH survival
There were 32 deaths (55 %) among males and 155 deaths
(48 %) among females. The 1-, 2-, 3-, and 5-year survival
estimates were 83.2 %, 68.7 %, 53.2 %, 45.6 % for males,
and 85.7 %, 75.7 %, 66.4 %, 57.4 % for females (Table 2).
The unadjusted median survival time for males was
3.8 years compared to a median survival of 6.5 years for fe-
males. There was no significant difference in Kaplan-Meier
survival curves, log-rank test p = 0.07 (Fig. 1). The un-
adjusted HR for the effect of male sex on survival was 1.43
(95 %CI 0.97, 2.13). After adjusting for baseline differences
Table 1 SSc-PAH baseline characteristics by sex
SSc patient characteristics Males Females Standardized
differencen = 58 n = 320
Age at PAH diagnosis, y,
mean (SD)
54.5 (11.0) 57.3 (13.0) 0.05
Time from SSc to PAH
diagnosis, y, mean (SD)
1.7 (14.0) 5.5 (14.2) 0.93a
PAH disease duration, y,
mean (SD)
3.5 (3.1) 4.7 (4.2) 0.29a
SSc manifestations
Diffuse subtype, n (%) 23 (40 %) 69 (22 %) 0.40a
Raynaud’s phenomenon,
n (%)
56 (97 %) 302 (94 %) 0.10
Telangiectasia, n (%) 46 (79 %) 224 (70 %) 0.22
Renal crisis, n (%) 11 (19 %) 26 (8 %) 0.32a
Esophageal dysmotility,
n (%)
51 (88 %) 276 (86 %) 0.05
Digital ulcers, n (%) 16 (28 %) 120 (38 %) 0.21
Interstitial lung disease,
n (%)
39 (67 %) 153 (48 %) 0.40a
ScL-70 antibody, n (%) 10 (17 %) 36 (11 %) 0.17
Anticentromere antibody,
n (%)
9 (15 %) 49 (17 %) 0.06
Cardiopulmonary measures
6MWD, m, mean (SD) 344.3 (140.9) 324.5 (154.6) 0.06
WHO functional class III-IV,
n (%)
24 (41 %) 124 (39 %) 0.05
mPAP, mmHg, mean (SD) 44.9 (20.5) 40.7 (21.7) 0.10
mPVR, dyn · s/cm5,
mean (SD)
705.0 (710.5) 584.7 (552.9) 0.19
Cardiac output L/min,
mean (SD)
4.2 (2.4) 3.3 (1.6) 0.26a
PCWP, mmHg, /mean (SD) 13.3 (6.2) 9.5 (6.2) 0.33a
BNP pg/mL, mean (SD) 203.0 (266.9) 245.9 (481.3) 0.19
FVC, % predicted 79.3 (17.4) 76.1 (24.6) 0.04
FEV1, % predicted 80.3 (18.2) 78.2 (26.1) 0.03
DLCO, ml/min/mmHg 52.1 (19.7) 55.3 (19.5) 0.06
Right ventricular enlargement
Normal 40 (69 %) 250 (78 %) 0.21
Mild 5 (9 %) 24 (8 %) 0.04
Moderate 10 (17 %) 35 (11 %) 0.18
Severe 3 (5 %) 11 (3 %) 0.09
Right ventricular dysfunction
Normal 39 (67 %) 249 (78 %) 0.23
Mild 5 (9 %) 26 (8 %) 0.02
Moderate 12 (21 %) 38 (12 %) 0.24
Severe 2 (3 %) 7 (2 %) 0.07




12 (21 %) 40 (13 %) 0.22
Hypertension, n (%) 13 (22 %) 88 (28 %) 0.12
Diabetes mellitus, n (%) 5 (9 %) 21 (7 %) 0.08
Hyperlipidemia, n (%) 8 (14 %) 26 (8 %) 0.18
Atrial fibrillation, n (%) 6 (10 %) 28 (9 %) 0.05
Peripheral vascular disease,
n (%)
3 (5 %) 19 (6 %) 0.03
Stroke, n (%) 2 (3 %) 15 (5 %) 0.06
SSc-PAH systemic sclerosis-associated pulmonary arterial hypertension, ScL-70
topoisomerase I, 6MWD 6-minute walk test, WHO World Health Organization,
mPAP mean pulmonary artery pressure, mPVR mean pulmonary vascular
resistance, PCWP pulmonary capillary wedge pressure, BNP brain natriuretic
peptide, FVC forced vital capacity, FEV1 forced expiratory volume 1, DLCO
diffusing capacity of the lungs for carbon monoxide
aDenotes standardized difference greater than 25 %
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disease subtype and interstitial lung disease, the HR for
male sex was attenuated to 1.27 (95 %CI 0.85, 1.90).
A sensitivity analysis was performed to explore the ef-
fect of PAH age of diagnosis >60 years that had been re-
ported by others. There was no significant difference in
survival curves between this subset of males and fe-
males, log-rank test 0.86 (Fig. 2). The unadjusted HR for
the effect of male sex on survival in those aged 60 years
or older was 1.06 (95 %CI 0.55, 2.07). There was a statis-
tically significant difference in survival curves for those
with an age of PAH diagnosis less than 60 years of age
(log-rank test p = 0.03, Fig. 3) with a male sex unadjusted
HR of 1.70 (1.04, 2.80). After adjusting for baseline dif-
ferences in disease subtype in this subset, the HR for
male sex was attenuated to 1.44 (95 %CI 0.85, 2.46).
Discussion
We have found that sex disparities appear to exist in
SSc-PAH. PAH is more common in females with SSc,
yet males have a shorter time from SSc to PAH diagno-
sis, shorter PAH disease duration and increased burden
of SSc disease. Despite these differences, male sex does
not independently impact SSc-PAH mortality. To our
knowledge, this is the largest study to examine the im-
pact of sex in SSc-PAH.
The female to male ratio for SSc-PAH of 5.5:1, is higher
than the reported sex ratios for SSc in general, ranging be-
tween 3–4:1 [7]. This suggests that PAH is an SSc disease
manifestation that occurs more frequently in females.
However, males with SSc-PAH have an increased fre-
quency of other serious SSc disease manifestations, not-
ably, scleroderma renal crisis, diffuse cutaneous disease
and interstitial lung disease. Furthermore, we found males
had a shorter time from SSc diagnosis to PAH diagnosis,
with the average male time to SSc-PAH diagnosis more
than 3 years earlier than females. In a Japanese cohort
study by Kasukawa et al. it was reported that a shortened
average time between SSc and SSc-PAH diagnosis was as-
sociated with an increase in mortality [21]. Together with
our findings, this may suggest that although PAH is less
frequent in males, they may have more aggressive disease.
The differential time to PAH diagnosis may also be reflect-
ive of sex-based differences is health-seeking behaviours
and/or access to care [7].
We found that females tended to have better short- and
long-term survival rates compared to males. However, sex
Table 2 SSc-PAH survival estimates by sex
Sex Survival
1-year 2-year 3-year 5-year Median
(95 %CI) (95 %CI) (95 %CI) (95 %CI) years
Male 83.2 % 68.7 % 53.2 % 45.6 % 3.8
(73.8 %, 93.9 %) (57.1 %, 82.8 %) (40.7 %, 69.4 %) (33.1 %, 62.8 %)
Female 85.7 % 75.7 % 66.4 % 57.4 % 6.5
(81.8 %, 89.7 %) (71.0 %, 80.8 %) (61.7 %, 72.7 %) (51.7 %, 63.7 %)
SSc-PAH systemic sclerosis-associated pulmonary arterial hypertension
Fig. 1 Kaplan-Meier survival curves for systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) cohort by sex
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was not found to be an independent factor for survival in
SSc-PAH patients. Condliffe et al. reported that male sex
was associated with decreased survival in a cohort of 259
patients with SSc-PAH [11]. MacGregor et al. reported
that although male sex was not an independent risk factor,
there was a trend toward increased death in male patients
with SSc-PAH [12]. In both studies, survival curves for
males and females were not provided so graphical com-
parisons to our findings could not be made. Visual inspec-
tion of our Kaplan-Meier curves suggests differential
survival between sexes, particularly in the long term. The
lack of statistical significance may be related to insufficient
power. However, accounting for baseline difference be-
tween sexes attenuated the HR toward a null effect. This
suggests that perceived differences in survival between
sexes in the full cohort are likely attributable to the base-
line differences in measured and unmeasured confounders.
When examining SSc-PAH patients with an age of PAH
diagnosis greater than 60 years, we found no significant
difference in survival between the sexes. Examination of
the Kaplan-Meier curves in this subset of patients, illus-
trates considerable overlap of the survival curves. It has
been hypothesized that because post-menopausal female
patients have lost the cardio-protective effect of estrogen,
Fig. 2 Kaplan-Meier survival curves for systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) patients with age greater than 60
at PAH diagnosis by sex
Fig. 3 Kaplan-Meier survival curves for systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) patients with age less than 60 at
PAH diagnosis by sex
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right ventricular adaptation is no longer possible. When
we evaluated survival in those with an age of PAH diagno-
sis less than age 60 years, there appeared to be sex-based
differences in survival. However the adjusted analysis sug-
gested that these perceived differences were attributable
to difference in other baseline characteristics. It may be
that the observed differences in SSc-PAH survival between
sexes reported in other studies may be attributable to un-
measured confounders.
A potential limitation of this study is the limited
power to detect small differences in survival. A larger
sample size would allow us to detect if male sex has a
small, independent effect on survival. To our knowledge,
this is the largest study to evaluate the effect of sex on
survival in SSc-PAH, and we had sufficient power to de-
tect moderate to large effects. A second potential limita-
tion is our ability to evaluate all aspects of SSc disease
burden. Although we were able to evaluate centromere
and ScL-70 antibodies, we did not have the ability to
evaluate other scleroderma-specific antibodies including
RNA polymerase III. In addition, interstitial lung disease
was present in a subset of patients. It should be noted
that these patients had mild disease, evidenced by bibasi-
lar reticulations on CT thorax. This may reflect a refer-
ral bias at our center as SSc patients with moderate to
severe interstitial lung disease, or pulmonary hyperten-
sion attributable to interstitial lung disease are not seen
on our Pulmonary Hypertension Clinic, but rather in the
Interstitial Lung Disease Clinic. As such, patients with
moderate to severe interstitial lung disease or pulmonary
hypertension attributable to interstitial lung disease were
not included in this analysis. Findings from this study
should not be generalized to those patients. In addition,
we did not collect smoking data. A third potential limi-
tation of our study was the inability to account for sex-
based differences in the psycho-social determinants of
health outcomes. Our cohort study occurs within the
context of a universal health care system, however it is
possible that inequitable outcomes may occur. These
may be related to sex-based differences in health-seeking
behaviors and access to care, which were beyond the
scope of this study. Future investigators may consider
accounting for these factors. Finally, our survival analysis
was limited to all-cause mortality. Since we did not have
access to death certificates, we were not able to report
cause-specific mortality. However there is controversy re-
garding the validity of cause-specific mortality obtained
from death certificates [22]. As such, our use of all-cause
mortality reflects a more conservative approach.
Conclusions
Sex-based disparities appear to exist in the frequency
of PAH, time to PAH diagnosis, PAH disease dur-
ation, and SSc disease burden. However, male sex does
not independently impact SSc-PAH survival. Similarly,
male sex does not independently affect survival in those
diagnosed with SSc-PAH after the age of 60. Further re-
search is needed to understand the basis for the differen-
tial frequency of PAH and time to diagnosis.
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